Y Intercept Hong Kong Ltd Buys Shares of 4,421 Repligen Co. (NASDAQ:RGEN)

Y Intercept Hong Kong Ltd purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) during the third quarter, Holdings Channel reports. The institutional investor purchased 4,421 shares of the biotechnology company’s stock, valued at approximately $658,000.

Several other institutional investors have also recently made changes to their positions in the company. First Turn Management LLC bought a new position in Repligen during the 3rd quarter worth about $13,202,000. Geneva Capital Management LLC boosted its stake in shares of Repligen by 8.5% during the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after purchasing an additional 10,908 shares in the last quarter. Banque Pictet & Cie SA increased its holdings in Repligen by 74.6% during the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after buying an additional 14,746 shares during the period. Thrivent Financial for Lutherans raised its stake in Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after buying an additional 425,061 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its holdings in Repligen by 20.0% during the second quarter. Integral Health Asset Management LLC now owns 60,000 shares of the biotechnology company’s stock worth $7,564,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $156.41 on Friday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market cap of $8.76 billion, a PE ratio of -422.72, a P/E/G ratio of 4.67 and a beta of 0.96. The business has a 50-day simple moving average of $142.66 and a two-hundred day simple moving average of $141.66.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period last year, the business earned $0.23 EPS. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.